{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:03:53Z","timestamp":1781096633484,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170198"],"award-info":[{"award-number":["82170198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02116-5","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T10:22:52Z","timestamp":1741947772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients"],"prefix":"10.1186","volume":"18","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuenan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"7339","key":"2116_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467\u201372.","journal-title":"Nature"},{"issue":"33","key":"2116_CR2","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911\u201320.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2116_CR3","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"116","author":"BA Walker","year":"2010","unstructured":"Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56-65.","journal-title":"Blood"},{"key":"2116_CR4","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.","journal-title":"Nat Commun"},{"issue":"1","key":"2116_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91\u2013101.","journal-title":"Cancer Cell"},{"issue":"6","key":"2116_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587\u201397.","journal-title":"Blood"},{"issue":"9","key":"2116_CR7","doi-asserted-by":"publisher","first-page":"e2104491","DOI":"10.1002\/advs.202104491","volume":"9","author":"X Feng","year":"2022","unstructured":"Feng X, Guo J, An G, Wu Y, Liu Z, Meng B, et al. Genetic aberrations and interaction of NEK2 and TP53 accelerate aggressiveness of multiple myeloma. Adv Sci (Weinh). 2022;9(9):e2104491.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2116_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13046-022-02276-7","volume":"41","author":"X Tang","year":"2022","unstructured":"Tang X, Deng Z, Ding P, Qiang W, Lu Y, Gao S, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022;41(1):85.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2116_CR9","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier SM, Mallm JP, Steiger S, Poos AM, Awwad MHS, Giesen N, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12(1):6960.","journal-title":"Nat Commun"},{"issue":"8","key":"2116_CR10","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1016\/j.apsb.2022.01.015","volume":"12","author":"R Wei","year":"2022","unstructured":"Wei R, Cui X, Min J, Lin Z, Zhou Y, Guo M, et al. NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma. Acta Pharm Sin B. 2022;12(8):3313\u201325.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"2116_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2012-06-430645","volume":"120","author":"NJ Bahlis","year":"2012","unstructured":"Bahlis NJ. Darwinian evolution and tiding clones in multiple myeloma. Blood. 2012;120(5):927\u20138.","journal-title":"Blood"},{"issue":"6","key":"2116_CR12","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","volume":"41","author":"M Dang","year":"2023","unstructured":"Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023;41(6):1032-47.e4.","journal-title":"Cancer Cell"},{"issue":"1","key":"2116_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-022-01648-z","volume":"21","author":"Y Liang","year":"2022","unstructured":"Liang Y, He H, Wang W, Wang H, Mo S, Fu R, et al. Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming. Mol Cancer. 2022;21(1):182.","journal-title":"Mol Cancer"},{"key":"2116_CR14","unstructured":"Mutational signatures across human cancer 2015 [Available from: https:\/\/cancer.sanger.ac.uk\/signatures\/signatures_v2\/."},{"issue":"7463","key":"2116_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"2","key":"2116_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100\u201313.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2116_CR17","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"2116_CR18","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol."},{"issue":"11","key":"2116_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC cancer gene census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18(11):696\u2013705.","journal-title":"Nat Rev Cancer"},{"issue":"7457","key":"2116_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u20138.","journal-title":"Nature"},{"issue":"2","key":"2116_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","volume":"34","author":"JJ Garc\u00e9s","year":"2020","unstructured":"Garc\u00e9s JJ, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia. 2020;34(2):589\u2013603.","journal-title":"Leukemia"},{"key":"2116_CR22","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2116_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cr.2007.115","volume":"18","author":"GM Li","year":"2008","unstructured":"Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18(1):85\u201398.","journal-title":"Cell Res"},{"issue":"5109","key":"2116_CR24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.8484122","volume":"260","author":"SN Thibodeau","year":"1993","unstructured":"Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260(5109):816\u20139.","journal-title":"Science"},{"issue":"3","key":"2116_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s005350200015","volume":"37","author":"H Yamamoto","year":"2002","unstructured":"Yamamoto H, Imai K, Perucho M. Gastrointestinal cancer of the microsatellite mutator phenotype pathway. J Gastroenterol. 2002;37(3):153\u201363.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2116_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","volume":"12","author":"P Zhao","year":"2019","unstructured":"Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2116_CR27","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/cancers13102452","volume":"13","author":"KA Frerichs","year":"2021","unstructured":"Frerichs KA, Verkleij CPM, Dimopoulos MA, Marin Soto JA, Zweegman S, Young MH, et al. Efficacy and safety of durvalumab combined with daratumumab in daratumumab-refractory multiple myeloma patients. Cancers (Basel). 2021;13(10):2452.","journal-title":"Cancers (Basel)."},{"issue":"9","key":"2116_CR28","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","volume":"6","author":"MV Mateos","year":"2019","unstructured":"Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e459\u201369.","journal-title":"Lancet Haematol"},{"issue":"1","key":"2116_CR29","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1111\/bjh.17448","volume":"194","author":"P Moreau","year":"2021","unstructured":"Moreau P, Ghori R, Farooqui M, Marinello P, San MJ. Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: cohort 2 of the phase I KEYNOTE-023 study. Br J Haematol. 2021;194(1):e48\u201351.","journal-title":"Br J Haematol"},{"key":"2116_CR30","doi-asserted-by":"publisher","first-page":"108382","DOI":"10.1016\/j.clim.2020.108382","volume":"214","author":"W Song","year":"2020","unstructured":"Song W, Zhang M. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin Immunol. 2020;214:108382.","journal-title":"Clin Immunol"},{"issue":"2","key":"2116_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2012.02.033","volume":"322","author":"J Ling","year":"2012","unstructured":"Ling J, Kumar R. Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett. 2012;322(2):119\u201326.","journal-title":"Cancer Lett"},{"issue":"9","key":"2116_CR32","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/ijc.34660","volume":"153","author":"ME Roche","year":"2023","unstructured":"Roche ME, Ko YH, Domingo-Vidal M, Lin Z, Whitaker-Menezes D, Birbe RC, et al. TP53 induced glycolysis and apoptosis regulator and monocarboxylate transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer. Int J Cancer. 2023;153(9):1671\u201383.","journal-title":"Int J Cancer"},{"key":"2116_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","volume":"39","author":"MA Weniger","year":"2016","unstructured":"Weniger MA, K\u00fcppers R. NF-\u03baB deregulation in Hodgkin lymphoma. Semin Cancer Biol. 2016;39:32\u20139.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2116_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41419-018-0881-6","volume":"9","author":"W Yang","year":"2018","unstructured":"Yang W, Liu L, Li C, Luo N, Chen R, Li L, et al. TRIM52 plays an oncogenic role in ovarian cancer associated with NF-kB pathway. Cell Death Dis. 2018;9(9):908.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2116_CR35","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-13-0987","volume":"20","author":"JC Godbersen","year":"2014","unstructured":"Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-\u03baB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014;20(6):1576\u201389.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2116_CR36","doi-asserted-by":"publisher","first-page":"19162","DOI":"10.1074\/jbc.M109.091645","volume":"285","author":"TS Jani","year":"2010","unstructured":"Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA. Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem. 2010;285(25):19162\u201372.","journal-title":"J Biol Chem"},{"key":"2116_CR37","doi-asserted-by":"publisher","first-page":"109790","DOI":"10.1016\/j.biopha.2019.109790","volume":"123","author":"H Cai","year":"2020","unstructured":"Cai H, Yan L, Liu N, Xu M, Cai H. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway. Biomed Pharmacother. 2020;123:109790.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2116_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ccr.2008.06.001","volume":"14","author":"F Bernassola","year":"2008","unstructured":"Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell. 2008;14(1):10\u201321.","journal-title":"Cancer Cell"},{"issue":"3","key":"2116_CR39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood.2019002102","volume":"136","author":"SA Swenson","year":"2020","unstructured":"Swenson SA, Gilbreath TJ, Vahle H, Hynes-Smith RW, Graham JH, Law HC, et al. UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells. Blood. 2020;136(3):299\u2013312.","journal-title":"Blood"},{"issue":"4","key":"2116_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36(4):561\u201384.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"2116_CR41","doi-asserted-by":"publisher","first-page":"BSR20221168","DOI":"10.1042\/BSR20221168","volume":"42","author":"X Han","year":"2022","unstructured":"Han X, Chen J, Wang J, Xu J, Liu Y. TTN mutations predict a poor prognosis in patients with thyroid cancer. Biosci Rep. 2022;42(7):BSR20221168.","journal-title":"Biosci Rep."},{"key":"2116_CR42","doi-asserted-by":"publisher","first-page":"111169","DOI":"10.1016\/j.biopha.2020.111169","volume":"135","author":"QX Zheng","year":"2021","unstructured":"Zheng QX, Wang J, Gu XY, Huang CH, Chen C, Hong M, et al. TTN-AS1 as a potential diagnostic and prognostic biomarker for multiple cancers. Biomed Pharmacother. 2021;135:111169.","journal-title":"Biomed Pharmacother"},{"key":"2116_CR43","doi-asserted-by":"publisher","first-page":"969070","DOI":"10.3389\/fpubh.2022.969070","volume":"10","author":"W Mao","year":"2022","unstructured":"Mao W, Zhou J, Hu J, Zhao K, Fu Z, Wang J, et al. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors. Front Public Health. 2022;10:969070.","journal-title":"Front Public Health"},{"issue":"1","key":"2116_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40164-022-00325-7","volume":"11","author":"SS Li","year":"2022","unstructured":"Li SS, Zhai XH, Liu HL, Liu TZ, Cao TY, Chen DM, et al. Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma. Exp Hematol Oncol. 2022;11(1):71.","journal-title":"Exp Hematol Oncol"},{"key":"2116_CR45","doi-asserted-by":"publisher","first-page":"878618","DOI":"10.3389\/fgene.2022.878618","volume":"13","author":"Q Zhu","year":"2022","unstructured":"Zhu Q, Wang J, Zhang W, Zhu W, Wu Z, Chen Y, et al. Whole-genome\/exome sequencing uncovers mutations and copy number variations in primary diffuse large B-cell lymphoma of the central nervous system. Front Genet. 2022;13:878618.","journal-title":"Front Genet"},{"issue":"2","key":"2116_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.leukres.2008.06.027","volume":"33","author":"H Chang","year":"2009","unstructured":"Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res. 2009;33(2):259\u201362.","journal-title":"Leuk Res"},{"key":"2116_CR47","doi-asserted-by":"publisher","first-page":"106687","DOI":"10.1016\/j.leukres.2021.106687","volume":"111","author":"K Gowin","year":"2021","unstructured":"Gowin K, Skerget S, Keats JJ, Mikhael J, Cowan AJ. Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment. Leuk Res. 2021;111:106687.","journal-title":"Leuk Res"},{"issue":"15","key":"2116_CR48","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"26","key":"2116_CR49","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2116_CR50","doi-asserted-by":"publisher","first-page":"188567","DOI":"10.1016\/j.bbcan.2021.188567","volume":"1876","author":"T Guardia","year":"2021","unstructured":"Guardia T, Eason M, Kontrogianni-Konstantopoulos A. Obscurin: a multitasking giant in the fight against cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188567.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"2116_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2021.11.016","volume":"526","author":"S Tuntithavornwat","year":"2022","unstructured":"Tuntithavornwat S, Shea DJ, Wong BS, Guardia T, Lee SJ, Yankaskas CL, et al. Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer. Cancer Lett. 2022;526:155\u201367.","journal-title":"Cancer Lett"},{"issue":"11","key":"2116_CR52","doi-asserted-by":"publisher","first-page":"e2215553120","DOI":"10.1073\/pnas.2215553120","volume":"120","author":"T Guardia","year":"2023","unstructured":"Guardia T, Zhang Y, Thompson KN, Lee SJ, Martin SS, Konstantopoulos K, et al. OBSCN restoration via OBSCN-AS1 long-noncoding RNA CRISPR-targeting suppresses metastasis in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2023;120(11):e2215553120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2116_CR53","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1101\/gad.282145.116","volume":"30","author":"NJ Dyson","year":"2016","unstructured":"Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 2016;30(13):1492\u2013502.","journal-title":"Genes Dev"},{"key":"2116_CR54","doi-asserted-by":"publisher","first-page":"215870","DOI":"10.1016\/j.canlet.2022.215870","volume":"547","author":"Y Yao","year":"2022","unstructured":"Yao Y, Gu X, Xu X, Ge S, Jia R. Novel insights into RB1 mutation. Cancer Lett. 2022;547:215870.","journal-title":"Cancer Lett"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02116-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02116-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02116-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:03:36Z","timestamp":1741950216000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02116-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2116"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02116-5","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Shanghai Changzheng Hospital (2016SL019A) and conducted in accordance with the the World Medical Association Declaration of Helsinki.\u00a0An informed consent protocol was used for this study and written informed consent was obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}